Impact of preserved and preservative-free latanoprost on the survival of conjunctival goblet cells

被引：0
|
作者：
Mouhammad, Z. Ahmad [1 ]
Brindstrup, C. Taul [1 ]
Begun, X. [1 ]
Nagymihaly, R. [2 ,3 ]
Heegaard, S. [4 ]
Petrovski, G. [2 ,3 ]
Kolko, M. [1 ,4 ]
机构：
[1] Univ Copenhagen, Dept Drug Design & Pharmacol, Copenhagen, Denmark
[2] Oslo Univ Hosp, Ctr Eye Res, Dept Ophthalmol, Oslo, Norway
[3] Univ Oslo, Inst Clin Med, Oslo, Norway
[4] Rigshosp Glostrup, Copenhagen Univ Hosp, Dept Ophthalmol, Glostrup, Denmark
来源：
ACTA OPHTHALMOLOGICA | 2018年 / 96卷
关键词：
D O I：
暂无
中图分类号：
R77 [眼科学];
学科分类号：
100212 ;
摘要：
S046
引用
收藏
页码：3 / 3
页数：1
相关论文
共 50 条
  • [21] Switch from BAK-preserved to preservative-free latanoprost decreases anterior chamber flare in POAG patients
    Kestelyn, Ph. A.
    Kestelyn, Ph. G.
    De Bacquer, D.
    Stevens, A. M.
    INTERNATIONAL OPHTHALMOLOGY, 2019, 39 (01) : 105 - 109
  • [22] Switch from BAK-preserved to preservative-free latanoprost decreases anterior chamber flare in POAG patients
    Kestelyn, Philippe G.
    De Bacquer, Dirk
    Stevens, Anna
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2014, 55 (13)
  • [23] Preservative-free versus preserved latanoprost eye drops in patients with open-angle glaucoma or ocular hypertension
    Aptel, Florent
    Choudhry, Reena
    Stalmans, Ingeborg
    CURRENT MEDICAL RESEARCH AND OPINION, 2016, 32 (08) : 1457 - 1463
  • [24] Switch from BAK-preserved to preservative-free latanoprost decreases anterior chamber flare in POAG patients
    Ph. A. Kestelyn
    Ph. G. Kestelyn
    D. De Bacquer
    A. M. Stevens
    International Ophthalmology, 2019, 39 : 105 - 109
  • [25] A phase III study comparing preservative-free latanoprost eye drop emulsion with preserved latanoprost in open-angle glaucoma or ocular hypertension
    Baudouin, Christophe
    Stalmans, Ingeborg
    Bourne, Rupert
    Larrosa, Jose Manuel
    Schmickler, Stefanie
    Seleznev, Aleksey
    Oddone, Francesco
    Phase III Study Group, Yosuf
    EYE, 2025,
  • [26] Tear cytokine profile of glaucoma patients treated with preservative-free or preserved latanoprost (vol 15, pg 723, 2017)
    Martinez-de-la-Casa, Jose M.
    Perez-Bartolome, Francisco
    Urcelay, Elena
    Santiago, Jose L.
    Moreno-Montanes, Javier
    Arriola-Villalobos, Pedro
    Benitez-del-Castillo, Jose M.
    Garcia-Feijoo, Julian
    OCULAR SURFACE, 2018, 16 (02): : 270 - 270
  • [27] BAK to the Future? Preserved and Preservative-Free Topical Glaucoma Medications
    Saeedi, Osamah
    Chen, Victoria
    EYE & CONTACT LENS-SCIENCE AND CLINICAL PRACTICE, 2022, 48 (04): : 139 - 140
  • [28] Ocular symptoms and signs with preserved and preservative-free glaucoma medications
    Jaenen, N.
    Baudouin, C.
    Pouliquen, P.
    Manni, G.
    Figueiredo, A.
    Zeyen, T.
    EUROPEAN JOURNAL OF OPHTHALMOLOGY, 2007, 17 (03) : 341 - 349
  • [29] In Vitro and In Vivo Comparative Toxicological Study of a New Preservative-Free Latanoprost Formulation
    Pauly, Aude
    Roubeix, Christophe
    Liang, Hong
    Brignole-Baudouin, Francoise
    Baudouin, Christophe
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2012, 53 (13) : 8172 - 8180
  • [30] Ocular Tolerability of Preservative-Free Tafluprost and Latanoprost: in vitro and in vivo Comparative Study
    Esaki, Yoshihiko
    Shimazaki, Atsushi
    Pellinen, Pertti
    OPEN OPHTHALMOLOGY JOURNAL, 2016, 10 : 146 - 153
12345